Maravai LifeSciences Holdings, Inc. $MRVI Shares Sold by Braidwell LP

Braidwell LP trimmed its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 15.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,702,921 shares of the company’s stock after selling 1,537,243 shares during the quarter. Maravai LifeSciences comprises 2.0% of Braidwell LP’s holdings, making the stock its 15th largest position. Braidwell LP’s holdings in Maravai LifeSciences were worth $54,306,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jane Street Group LLC boosted its position in Maravai LifeSciences by 1,463.1% in the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock valued at $841,000 after buying an additional 356,067 shares during the last quarter. Creative Planning raised its position in Maravai LifeSciences by 49.6% during the 2nd quarter. Creative Planning now owns 116,031 shares of the company’s stock worth $280,000 after buying an additional 38,450 shares during the last quarter. Rhumbline Advisers raised its position in Maravai LifeSciences by 20.3% during the 2nd quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock worth $471,000 after buying an additional 32,940 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Maravai LifeSciences during the 2nd quarter valued at approximately $36,000. Finally, Invesco Ltd. boosted its holdings in shares of Maravai LifeSciences by 16.8% in the 2nd quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock valued at $680,000 after acquiring an additional 40,495 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the transaction, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Maravai LifeSciences Trading Up 1.1%

Maravai LifeSciences stock opened at $7.38 on Thursday. The company has a current ratio of 4.05, a quick ratio of 2.98 and a debt-to-equity ratio of 0.49. Maravai LifeSciences Holdings, Inc. has a 12 month low of $2.30 and a 12 month high of $9.42. The stock’s 50 day simple moving average is $6.73 and its two-hundred day simple moving average is $4.86. The firm has a market cap of $1.92 billion, a PE ratio of -14.19 and a beta of 0.60.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $51.44 million during the quarter, compared to analyst estimates of $48.67 million. Analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MRVI shares. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Wall Street Zen downgraded shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wells Fargo & Company lifted their price objective on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.25.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.